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Matt KaeberleinAbstract
Understanding the genetic basis of age-related
diseases is a critical step toward developing therapies
that promote healthy aging. Numerous genes have
been identified that modulate lifespan, but the
influence of natural variation in aging has not been
well studied. A new report utilizing a transgenic
protein aggregation model in Caenorhabditis elegans
has provided important tools and insights into the
relationship between natural genetic variation, protein
aggregation, and age-related pathology.
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Age is the single greatest risk factor for a majority of the
major causes of death and disability in developed
countries [1]. As populations in these nations continue
to achieve greater life expectancies, the increase in
prevalence of age-associated diseases presents a particu-
larly challenging problem. One important class of age-
associated diseases, including Alzheimer’s and other
neurodegenerative diseases, can be attributed to a failure
to maintain protein homeostasis resulting in the accu-
mulation of toxic proteins over time. Identifying the
genetic factors that modulate why this happens in the
context of an aging organism and, equally importantly,
why it does not happen the same way in every individ-
ual, is essential for developing therapies that can delay
or prevent these disorders. In this issue of BMC Biology,
Gidalevitz et al. [2] characterize a series of genetically
dissimilar transgenic C. elegans strains designed to assess
the contribution of natural genetic variation to age-
associated protein aggregation and toxicity. In theCorrespondence: kaeber@uw.edu
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stated.process they discovered that not only does natural gen-
etic variation dramatically influence the propensity of
proteins to aggregate, but that aggregation and toxicity
are not strongly correlated.
C. elegans has been utilized extensively as a model sys-
tem to study human diseases of proteotoxicity, a term
used to refer to the detrimental effects of misfolded or
aggregated proteins on cells. Human proteotoxic dis-
eases include prion disorders, motor neuron disease,
and various amyloidoses, as well as Alzheimer’s,
Huntington’s and Parkinson’s diseases. In addition to the
powerful genetic tools available to C. elegans researchers,
several features make C. elegans a particularly useful
model in this regard. These include the relative ease of
making transgenic lines, the fact that adult C. elegans
germ line), and that an adult lifespan is two to three
weeks for animals maintained in the lab. These features
make it possible to express an aggregation-prone or
toxic peptide of choice transgenically, either broadly or
in a cell-type restricted manner, and, if fused to a fluor-
escent reporter such as GFP (green fluorescent protein)
or YFP (yellow fluorescent protein), watch the formation
of protein aggregates as the animals get older. Precisely
this approach has been taken with several human
disease-related peptides, including beta amyloid, tau,
TDP-43, and alpha synuclein [3]. Although each toxic
peptide has its own unique features and kinetics of
toxicity, there are striking similarities between these dif-
ferent transgenic lines, including common genetic modi-
fiers and clear age-associated pathology. In a majority of
cases, toxic peptides have been expressed either
neuronally or in body wall muscle cells, with body wall
muscle expression yielding a robust age-associated par-
alysis phenotype, while neuronal expression tends to
yield more subtle age-associated changes in movement
or behavior, with accompanying cell loss in some cases.
Among the most utilized of these strains are a series
of transgenic lines expressing polyglutamine peptides of
varying length fused to YFP that were generated by thed. This is an Open Access article distributed under the terms of the Creative
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different proteins underlie several human diseases, in-
cluding Huntington’s, spinobulbar muscular atrophy,
dentatorubral-pallidoluysian atrophy and several
spinocerebellar ataxias. As in the human diseases, the
polyglutamine-YFP peptides show age-dependent
aggregation, with the rapidity of aggregation and cyto-
toxicity correlating strongly with the length of the
polyglutamine repeat. Although it remains unclear how
well these C. elegans strains recapitulate other major
aspects of human polyglutamine diseases, there is no
question that they have been, and continue to be, useful
tools for understanding the genetic and molecular
mechanisms of proteotoxicity.
One of the primary discoveries to come from studies
of transgenic polyglutamine toxicity, as well as the other
proteotoxicity models, in C. elegans is that the same
genetic and environmental features that modulate aging
also modulate resistance to proteotoxic stress. This
makes intuitive sense, since proteotoxic diseases are gen-
erally age-associated; however, it also strongly supports
the hypothesis that loss of protein homeostasis may be a
contributing causal factor for aging, particularly in post-
mitotic cells and tissues. Consistent with this idea, studies
have shown that three of the best-studied longevity path-
ways in C. elegans, the insulin-like signaling pathway [6],
dietary restriction [7], and the hypoxic response pathway
[8], all similarly modulate resistance to polyglutamine tox-
icity. Several additional important observations have also
come from these and similar studies.
The first of these important observations is that aggre-
gation does not necessarily reflect toxicity, at least for
muscle cells. At least two lines of evidence support this
idea. First, when polyglutamine is expressed in body wall
muscle cells, dietary restriction extends lifespan and dra-
matically suppresses toxicity (defined here by onset of
age-associated paralysis), without reducing the number
or distribution of large polyglutamine aggregates [7].
Second, reduced signaling through the insulin signaling
pathway appears to suppress proteotoxicity by two dis-
tinct mechanisms: heat shock factor one (HSF-1) pro-
motes disaggregation of toxic intermediates while the
FOXO transcription factor DAF-16 promotes the forma-
tion of large molecular weight aggregates, which are ap-
parently no longer toxic [9].
A second important observation is that exogenous
proteotoxicity can affect healthspan without affecting life-
span. Expression of a 40-glutamine-repeat peptide fused
to YFP in body wall muscle cells causes nearly all animals
to become paralyzed by around 2 weeks of adulthood
without significantly affecting adult lifespan [7].
And a third important observation is that protein
homeostasis declines during normal aging. Even in ani-
mals that do not express a toxic transgenic peptide,there is now substantial evidence that misfolded and ag-
gregated proteins accumulate with age [10]. This has led
to the hypothesis that a disease-causing aggregation-
prone mutant protein can serve as a ‘seed’ to initiate a
toxic cascade of protein misfolding and aggregation that
amplifies the underlying age-associated increase in
proteotoxic stress.
Despite these insights into the role of protein homeo-
stasis in disease, one missing link has been connecting
natural variation to protein homeostasis and aging. The
vast majority of genetic studies in this area have been
performed using RNA interference knockdown or muta-
tions (often gene deletions) derived from chemical muta-
genesis. Gidalevitz et al. [2] have taken the first step in
addressing this limitation by crossing the aforemen-
tioned muscle-specific 40 polyglutamine-YFP peptide
into three genetically dissimilar wild C. elegans strains
and then creating a series of recombinant inbred lines.
Just in the process of creating these lines, the authors
noted that genetic background strongly influences the
phenotypic response (degree and rate of paralysis) to ex-
pression of the toxic peptide, as well as which subsets of
muscle cells are most likely to form aggregates. In
addition, they provided further confirmation that the
formation of large aggregates does not always correlate
strongly with toxicity, and that this relationship is likely
influenced by the underlying genetic background.
Going forward, these new transgenic tools will help
define the role of natural genetic variation in protein
homeostasis and aging. It will be of particular interest to
see which new genes are implicated in this process and
whether they fall into the established pathways or define
new and previously unsuspected mechanisms. It will also
be of interest to determine whether the same genes
modulate age-related diseases in mammals. Ultimately,
as we learn more about how and why protein homeosta-
sis breaks down during aging it should be possible to
slow, or perhaps even prevent, that breakdown.
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